Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Genesis ; 54(5): 277-85, 2016 05.
Article in English | MEDLINE | ID: mdl-26919034

ABSTRACT

The transcription factor forkhead box protein A1 (FOXA1) plays a critical role in the proliferation of human breast cancer cells, particularly estrogen receptor alpha (ERα)-positive luminal breast cancer cells. However, genetic studies of the requirement for Foxa1 in mammary tumor formation in mice have been hampered by the lack of a conditional gene ablation. We examined three mouse models of mammary-specific ablation of Foxa1 in ductal epithelial cells to identify the best system for complete and mammary-specific ablation of Foxa1. We found that MMTV-Cre and MMTV-rtTA;Tet-On-Cre led to partial deletion of Foxa1 and attenuated mammary duct formation, whereas Krt14-Cre led to complete ablation of Foxa1 and abolished mammary duct formation, in Foxa1(loxP/loxP) mice. These results demonstrate that Foxa1 is essential for mammary duct formation, and reveal a series of mouse models in which mammary expression of Foxa1 can be attenuated or completely blocked. Our study also suggests a potentially powerful model for complete ablation of Foxa1 in mammary epithelial cells using Krt14-driven Cre expression in an inducible manner, such as Krt14-rtTA;Tet-On-Cre. This model system will facilitate further in vivo functional studies of Foxa1 or other factors in mammary gland development and tumor formation and progression. genesis 54:277-285, 2016. © 2016 Wiley Periodicals, Inc.


Subject(s)
Cell Proliferation/genetics , Hepatocyte Nuclear Factor 3-alpha/genetics , Mammary Glands, Animal/growth & development , Animals , Epithelial Cells/metabolism , Female , Humans , Integrases/genetics , Keratin-14/genetics , Mammary Glands, Animal/metabolism , Mice , Mice, Transgenic
2.
Mol Carcinog ; 54(5): 393-404, 2015 May.
Article in English | MEDLINE | ID: mdl-24293218

ABSTRACT

Our aim was to better understand peroxisome proliferator-activated receptor gamma (PPARγ)-independent pathways involved in anti-cancer effects of thiazolidinediones (TZDs). We focused on Δ2-troglitazone (Δ2-TGZ), a PPARγ inactive TZD that affects breast cancer cell viability. Appearance of TUNEL positive cells, changes in mitochondrial membrane potential, cleavage of poly(ADP-ribose) polymerase (PARP)-1 and caspase-7 revealed that apoptosis occurred in both hormone-dependent MCF7 and hormone-independent MDA-MB-231 breast cancer cells after 24 and 48 h of treatment. A microarray study identified endoplasmic reticulum (ER) stress as an essential cellular function since many genes involved in ER stress were upregulated in MCF7 cells following Δ2-TGZ treatment. Δ2-TGZ-induced ER stress was further confirmed in MCF7 cells by phosphorylation of pancreatic endoplasmic reticulum kinase-like endoplasmic reticulum kinase (PERK) and its target eIF2α after 1.5 h, rapid increase in activating transcription factor (ATF) 3 mRNA levels, splicing of X-box binding protein 1 (XBP1) after 3 h, accumulation of binding immunogloblulin protein (BiP) and CCAAT-enhancer-binding protein homologous protein (CHOP) after 6 h. Immunofluorescence microscopy indicated that CHOP was relocalized to the nucleus of treated cells. Similarly, in MDA-MB-231 cells, overexpression of ATF3, splicing of XBP1, and accumulation of BiP and CHOP were observed following Δ2-TGZ treatment. In MCF7 cells, knock-down of CHOP or the inhibition of c-Jun N-terminal kinase (JNK) did not impair cleavage of PARP-1 and caspase-7. Altogether, our results show that ER stress is an early response of major types of breast cancer cells to Δ2-TGZ, prior to, but not causative of apoptosis.


Subject(s)
Apoptosis/drug effects , Breast Neoplasms/pathology , Chromans/pharmacology , Endoplasmic Reticulum Stress/drug effects , Endoplasmic Reticulum/drug effects , Hypoglycemic Agents/pharmacology , PPAR gamma/antagonists & inhibitors , Thiazolidinediones/pharmacology , Biomarkers, Tumor , Blotting, Western , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Caspase 7/genetics , Caspase 7/metabolism , Cell Cycle/drug effects , Cell Proliferation/drug effects , Chromans/chemistry , Endoplasmic Reticulum/metabolism , Female , Fluorescent Antibody Technique , Humans , In Situ Nick-End Labeling , JNK Mitogen-Activated Protein Kinases/genetics , JNK Mitogen-Activated Protein Kinases/metabolism , PPAR gamma/genetics , PPAR gamma/metabolism , Phosphorylation/drug effects , Poly(ADP-ribose) Polymerases/genetics , Poly(ADP-ribose) Polymerases/metabolism , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Thiazolidinediones/chemistry , Transcription Factor CHOP/genetics , Transcription Factor CHOP/metabolism , Troglitazone , Tumor Cells, Cultured
3.
Eur J Med Chem ; 83: 129-40, 2014 Aug 18.
Article in English | MEDLINE | ID: mdl-24953030

ABSTRACT

Δ2-Troglitazone derivatives were shown to exhibit anti-proliferative activity in a PPARγ-independent manner. We prepared various compounds in order to increase their potency and decrease their toxicity towards non-malignant primary cultured hepatocytes. Many compounds induced viabilities less than 20% at 10 µM on various cancer cell lines. Furthermore, five of them showed hepatocyte viability of 80% or more at 200 µM. In addition, compounds 17 and 18 exhibited promising maximum tolerated doses on a murine model, enabling future investigations.


Subject(s)
Antineoplastic Agents/pharmacology , Antineoplastic Agents/toxicity , Chromans/pharmacology , Chromans/toxicity , Drug Design , Thiazolidinediones/pharmacology , Thiazolidinediones/toxicity , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Chromans/chemistry , Hepatocytes/cytology , Hepatocytes/drug effects , Humans , Thiazolidinediones/chemistry , Troglitazone
SELECTION OF CITATIONS
SEARCH DETAIL
...